Arvinas, Inc. ARVN

US Pharmaceuticals

$6.65 ▼ -1.63% ($-0.11)

Open $6.63

Prev Close $6.76

Day Range $6.55 – $6.82

52W Range $6.33 – $14.51

Market Cap $442.68M

Beta 1.79

EPS (TTM) $-0.18

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2018-09-27
Shares Out.	65,390,000
Website	arvinas.com/ ↗
Phone	12035351456
Employees	246
Revenue	$500,000
Gross Profit	$400,000
Net Income	-$53.9M
Free Cash Flow	-$159.8M
Total Assets	$607.5M
Total Liabilities	$93.7M
Equity	$513.8M

About Arvinas, Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Arvinas, Inc. is a publicly traded company under the ticker symbol ARVN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.